Australia's most trusted
source of pharma news
Posted 6 May 2025 AM
Mature drugs at the top of the highest earners list still posted significant double digit, year-on-year growth on the PBS in the first quarter of this year.
Total pre-rebate spending on the R/PBS also grew sharply, increasing 30.5 per cent for Q1 2025 year-on-year, costing an extra $1.28 billion. However, most of this was due to new listings, with the top 10 adding a combined $260.7 million to the PBS, according to a Pharma in Focus analysis of data provided by Services Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.